NCT05972564View on ClinicalTrials.gov

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 30, 2026

Conditions
ObesityMetabolic Syndrome
Interventions
DRUG

Empagliflozin 25 MG

Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.

DRUG

Placebo

Placebo consists of gelatin capsules.

Trial Locations (1)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER